This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
In Stockhead: Race Oncology races ahead in FY24 with key milestones
Race Oncology is pleased to release the FY24 annual report. Key highlights include:
- Race Oncology hails significant FY24 with several key milestones achieved
- First batch of (cGMP) manufacturing and toxicology study successfully completed for Race’s new bisantrene formulation RC220
- Preclinical work in the past year has demonstrated the drug’s potent cancer killing effect
Read the full report via this link.